Want to see IN:THYROCARE full AI Analyst Report?
Top Page
Thyrocare Technologies Ltd
(THYROCARE)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹657.00
▲(8.55% Upside)
Action:Reiterated
Date:08/11/26
The score is driven primarily by strong financial quality (low leverage, improving ROE, and strong cash conversion) and supportive technical momentum with price above all major moving averages. The main offsets are a relatively high P/E multiple with only a modest dividend yield, and near-overbought technical readings that may constrain short-term performance.
Positive Factors
Low leverage and improving returns
The very low debt-to-equity ratio gives Thyrocare financial flexibility and reduces balance-sheet strain. At the same time, sharply higher ROE indicates that the company is using its equity base more effectively, supporting durable profitability and capacity to fund future operations.
Negative Factors
Volatile profitability
Historical margin volatility makes it harder to assume that the current profitability level will persist. Sharp changes in gross margin can reduce earnings visibility and may limit management’s ability to plan investment, pricing, and shareholder distributions with confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and improving returns
The very low debt-to-equity ratio gives Thyrocare financial flexibility and reduces balance-sheet strain. At the same time, sharply higher ROE indicates that the company is using its equity base more effectively, supporting durable profitability and capacity to fund future operations.
Read all positive factors
Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹91.70B
Dividend Yield1.62%
Average Volume (3M)174.32K
Price to Earnings (P/E)33.6
Beta (1Y)0.56
Revenue Growth21.09%
EPS Growth65.51%
CountryIN
Employees2,092
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)17.15
Shares Outstanding159,165,310
10 Day Avg. Volume33,259
30 Day Avg. Volume174,322
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)9.48
Price to Sales (P/S)6.69
P/FCF Ratio28.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.27
Revenue Forecast (FY)₹9.92B
Thyrocare Technologies Ltd Business Overview & Revenue Model
Company Description
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across...
How the Company Makes Money
Thyrocare primarily makes money by providing diagnostic testing services for a fee. Its main revenue stream is the sale of pathology/laboratory tests and bundled preventive health check-up packages, where customers (individuals or institutions) pa...
Thyrocare Technologies Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.76B | 8.29B | 6.87B | 5.72B | 5.27B | 5.89B |
| Gross Profit | 4.46B | 3.10B | 4.96B | 1.81B | 3.63B | 4.19B |
| EBITDA | 2.88B | 2.65B | 2.04B | 1.48B | 1.31B | 2.64B |
| Net Income | 1.76B | 1.63B | 915.10M | 707.60M | 644.90M | 1.76B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 7.47B | 6.93B | 6.44B | 6.33B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 2.31B | 1.92B | 1.77B | 1.51B | 1.39B |
| Total Debt | 0.00 | 506.90M | 246.80M | 423.40M | 233.10M | 207.00M |
| Total Liabilities | -5.86B | 1.61B | 1.46B | 1.16B | 975.00M | 810.90M |
| Stockholders Equity | 5.86B | 5.86B | 5.47B | 5.27B | 5.34B | 5.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.11B | 1.95B | 1.46B | 1.06B | 856.60M | 755.80M |
| Operating Cash Flow | 1.27B | 2.16B | 1.91B | 1.68B | 1.29B | 1.13B |
| Investing Cash Flow | 47.10M | -260.80M | -525.20M | -912.80M | -389.90M | -235.70M |
| Financing Cash Flow | -1.18B | -1.70B | -1.30B | -848.00M | -861.80M | -894.10M |
Thyrocare Technologies Ltd Technical Analysis
Neutral
605.25
Price Trends
573.32
Positive
522.67
Positive
471.31
Positive
Market Momentum
0.38
Positive
46.77
Neutral
20.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Neutral. The current price of 605.25 is above the 20-day moving average (MA) of 598.04, above the 50-day MA of 573.32, and above the 200-day MA of 471.31, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 46.77 is Neutral, neither overbought nor oversold. The STOCH value of 20.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:THYROCARE.
Thyrocare Technologies Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | ₹28.40B | 35.81 | ― | 0.31% | 14.22% | 7.17% | |
78 Outperform | ₹91.70B | 33.61 | ― | 1.62% | 21.09% | 65.51% | |
74 Outperform | ₹314.70B | 58.42 | ― | 0.85% | 14.29% | 5.55% | |
71 Outperform | ₹154.12B | 81.73 | ― | 0.13% | 20.18% | 24.71% | |
61 Neutral | ₹18.14B | 18.71 | ― | 0.49% | 10.19% | 20.99% | |
59 Neutral | ₹122.35B | 60.67 | ― | 0.34% | 21.80% | 31.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:THYROCARE
Thyrocare Technologies Ltd
576.15
143.25
33.09%
IN:KRSNAA
Krsnaa Diagnostics Limited
559.25
-265.79
-32.22%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,874.90
292.56
18.49%
IN:METROPOLIS
Metropolis Healthcare Ltd.
589.95
53.77
10.03%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,496.35
390.05
35.26%
IN:VIMTALABS
Vimta Labs Limited
635.50
-194.69
-23.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.